Portfolio companies news

19 October 2016

Ganaxolone Phase 1 Data Supports Progressing to Phase 2 in Patients with Status Epilepticus

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that in its Phase 1 dose-escalation study, ganaxolone intravenous (IV) achieved dose levels targeted for efficacy in patients with status epilepticus (SE) and other indications. Status epilepticus is a life-threatening medical emergency associated with high mortality and limited treatments. Typically, single or combination IV antiepileptic drugs are used in an attempt to break the seizures, however there are approximately 45,000 patients in the U.S. who do not respond to first-line treatment.

03 October 2016

Four NovaMedica Executives are in the Top-1000 Russian Managers Rating Released by the Managers Association of Russia and Kommersant Publishing House

Four NovaMedica executives are among the business leaders listed in the Top-1000 Russian Managers rating released annually by the Managers Association of Russia and Kommersant Publishing House.

29 September 2016

Ganaxolone Reduces Seizures in Females with PCDH19 Pediatric Epilepsy

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced top-line results from a Phase 2 exploratory open-label clinical trial evaluating ganaxolone, its CNS-selective GABAA modulator, in females with PCDH19 pediatric epilepsy. In the trial, ganaxolone reduced seizure frequency from baseline in the majority of patients enrolled in the study and was generally safe and well tolerated. PCDH19 pediatric epilepsy is a rare, serious epilepsy characterized by early-onset cluster seizures, cognitive and sensory impairment, and behavioral disturbances, with no approved treatments. In 2015, the U.S. Food and Drug Administration granted Orphan Drug Designation to ganaxolone for the treatment of PCDH19.

20 September 2016

Allergan to Acquire Tobira Therapeutics Expanding Global GI R&D Pipeline and Taking a Leading R&D Position in NASH

Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases, today announced that they have entered into a definitive agreement under which  Allergan  will acquire Tobira for an upfront payment of  $28.35  per share, in cash, and up to  $49.84  per share in Contingent Value Rights (CVRs) that may be payable based on the successful completion of certain development, regulatory and commercial milestones, for a total potential consideration of up to  $1.695 billion . The Boards of Directors of both companies have unanimously approved the transaction.

12 September 2016

Miramar Labs’ CEO Interviewed on Bloomberg Radio

Miramar Labs, Inc., (OTCQB:MRLB), a global aesthetic company, announced today that the company’s CEO, Mike Kleine, was interviewed on Bloomberg Radio’s “Taking Stock” on September, 12th, 2016 at 3:15pm EDT.

12 September 2016

Tobira Therapeutics Announces Initiation of Phase 1 Combination Study of Cenicriviroc and Evogliptin

Tobira Therapeutics, Inc. (NASDAQ:TBRA), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases, today announced the initiation of a Phase 1 study of cenicriviroc (CVC) in combination with evogliptin (EVO).

07 September 2016

Tobira Therapeutics Announces Appointment of Dr. Laurent Fischer as Industry Co-chair of the Liver Forum Steering Committee

Tobira Therapeutics, Inc. (NASDAQ:TBRA), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases, today announced that Laurent Fischer, M.D., the company’s chief executive officer, has been appointed to serve on the Liver Forum’s steering committee. The steering committee provides overall scientific leadership to the Liver Forum. The goal of the Liver Forum is to leverage the scientific community’s collective knowledge and experience with therapies to facilitate drug development for the treatment of liver disease.

31 August 2016

ReVision Optics Announces First U.S. Commercial Cases of Raindrop® Near Vision Inlay

ReVision Optics, Inc., a leader in implantable presbyopia-correcting corneal inlay technology, announces the U.S. commercial launch of the Raindrop® Near Vision Inlay. The initial launch plan calls for the company’s direct field force to focus on sites that participated in the U.S. IDE clinical trial, followed by a more broad-based expansion later in 2016.

30 August 2016

Miramar Labs, Inc.® Appoints Patrick F. Williams To Board of Directors

Miramar Labs, Inc., (MRLB), a global aesthetic company, announced today the appointment of Patrick F. Williams to the Company’s Board of Directors. Mr. Williams will serve as Chairman of the Audit Committee, bringing nearly 20 years of financial management experience.

18 August 2016

ReVision Optics Secures $10 Million Credit Facility from Square 1 Bank

ReVision Optics®, Inc. (RVO), a leader in implantable presbyopia-correcting corneal inlay technology, today announced that it has secured a $10 million credit facility from Square 1 Bank, a division of Pacific Western Bank. RVO announced receipt of U.S. Food and Drug Administration (FDA) approval for its Raindrop® Near Vision Inlay for the surgical correction of presbyopia on June 29, 2016. Proceeds from the credit facility will be used for working capital purposes including commercial operations.